The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

British Journal of Haematology

Volumn 158, Issue 4, 2012, Pages 519-522

  Burnett, Alan K ^a   Russell, Nigel H ^b   Culligan, Dominic ^c   Cavanagh, Jamie ^d   Kell, Jonathan ^e   Wheatley, Keith ^f   Virchis, Andra ^g   Hills, Robert K ^a   Milligan, Donald ^h  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g BARNET HOSPITAL   (United Kingdom)

^h BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

AML; Chemotherapy; Clinical trial; Elderly

Indexed keywords

CYTARABINE; TIPIFARNIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER REGRESSION; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HEART DISEASE; HUMAN; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SOLID TUMOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; QUINOLONES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84864295735     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09165.x     Document Type: Article

References (13)

1. Basso, A.D., Kirschmeier, P. & Bishop, W.R. (2006) Lipid posttranslational modifications. Farnesyl transferase inhibitors. Journal of Lipid Research, 47, 15-31.
2. Burnett, A.K., Milligan, D., Prentice, A.G., Goldstone, A.H., McMullin, M.F., Hills, R.K. & Wheatley, K. (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 109, 1114-1124.
3. Cohen, S.J., Ho, L., Ranganathan, S., Abbruzzese, J.L., Alpaugh, R.K., Beard, M., Lewis, N.L., MacLaughlin, S., Rogatko, A., Preez-Ruixo, J.J., Thistle, A.M., Verhaeghe, T., Wang, H., Weiner, L.M., Wright, J.J., Hudes, G.R. & Meropol, N.J. (2003) Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology, 21, 1301-1306.
4. Cox, A.D. & Der, C.J. (2002) Farnesyl transferase inhibitors: promises and realities. Current Opinion in Chemical Biology, 2, 388-393.
5. End, D.W., Smets, G., Todd, A.V., Applegate, T.L., Fuery, C.J., Angibaud, P., Venet, M., Sanz, G., Poignet, H., Skrzat, S., Devine, A., Wouters, W. & Bowden, C. (2001) Characterization of the antitumor effects of the selective farnesyl protein transfease inhibitor R115777 in vivo and in vitro. Cancer Research, 61, 131-137.
6. Harousseau, J.-L., Martinelli, G., Jedrzejczak, W.W., Brandwein, J.M., Bordessoule, D., Masszi, T., Ossenkoppele, G.J., Alexeeva, J.A., Beutel, G., Maertens, J., Vidriales, M.-B., Dombret, H., Thomas, X., Burnett, A.K., Robak, T., Khuageva, N.K., Golenkov, A.K., Tothova, E., Mollgard, L., Park, Y.C., Bessems, A., De Porre, P. & Howes, A.J. for the FIGHT-AML-301 Investigators. (2009) A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood, 114, 1166-1173.
7. Hills, R.K. & Burnett, A.K. (2011) Applicability of a 'Pick a Winner' trial design to acute myeloid leukemia. Blood, 118, 2389-2394.
8. Karp, J.E., Lancet, J.E., Kaufmann, S.H., End, D.W., Wright, J.J., Bol, K., Horak, I., Tidwell, M.L., Liesveld, J., Kottke, T.J., Ange, D., Buddharaju, L., Gojo, I., Highsmith, W.E., Belly, R.T., Hohl, R.J., Rybak, M.E., Thibault, A. & Rosenblatt, J. (2001) Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood, 97, 3361-3369.
9. Lancet, J.E., Gojo, I., Gotlib, J., Feldman, E.J., Greer, J., Liesveld, J.L., Bruzek, L.M., Morris, L., Park, Y., Adjei, A.A., Kaufmann, S.H., Garrett-Mayer, E., Greenberg, P.L., Wright, J.J. & Karp, J.E. (2007) A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood, 109, 1387-1394.
10. Phillips, M.R. & Cox, A.D. (2007) Geranyl transferase I as a target for anti-cancer drugs. Journal of Clinical Investigation, 117, 1223-1225.
11. Rao, S., Cunningham, D., de Gramont, A., Scheithauer, W., Smakal, M., Humblet, Y., Kourteva, G., Iveson, T., Andre, T., Dostalova, J., Illes, A., Belly, R., Perez-Ruixo, J.J., Park, Y.C. & Palmer, P.A. (2004) Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. Journal of Clinical Oncology, 22, 3950-3957.
12. Wheatley, K., Brookes, C.L., Howman, A.J., Goldstone, A.H., Milligan, D.W., Prentice, A.G., Moorman, A.V. & Burnett, A.K. for the United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup. (2009) Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. British Journal of Haematology, 145, 598-605.
13. Zhang, B., Prendergast, G.C. & Fenton, R.G. (2002) Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Research, 62, 450-458.